LLY Eli Lilly and Co

   By Josh Beckerman 
 

Eli Lilly & Co. (LLY) reported favorable results for its Cyramza cancer drug in the Phase 3 Reach-2 trial with liver cancer patients.

The company said Reach-2 showed a statistically significant improvement in the primary endpoint of overall survival and in the secondary endpoint of progression-free survival.

The trial evaluated the drug with a biomarker-selected patient population.

Cyramza, currently approved for some patients with conditions including gastric cancer, is being investigated in a development program that has enrolled more than 14,000 patients in over 100 trials.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

January 18, 2019 20:08 ET (01:08 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.